Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors

Berman, E., Girotra, M., Cheng, C., Chanel, S., Maki, R., Shelat, M., Strauss, H. W., Fleisher, M., Heller, G., Farooki, A. (July 2013) Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk Res, 37 (7). pp. 790-4. ISSN 1873-5835 (Electronic)0145-2126 (Linking)

URL: https://www.ncbi.nlm.nih.gov/pubmed/23473999
DOI: 10.1016/j.leukres.2013.02.005

Abstract

Patients with chronic myelogenous leukemia (CML) or gastrointestinal stromal tumors (GIST) who take imatinib have abnormalities of bone metabolism. However, it is unclear what impact these changes have on bone mineral density (BMD). We prospectively analayzed levels of osteocalcin, a marker of bone formation secreted by osteoblasts, and serum N-telopeptide of type I collagen (NTX), a marker of bone resorption, as well as other minerals involved in bone metabolism in 19 patients with either CML or GIST We correlated these results with changes in bone mineral density as measured by serial dual energy X-ray absorptiometry (DEXA) scans over a two year period. Osteocalcin levels were low in 95% of patients and 37% had no measurable amount. Levels of NTX were less consistent. Nine patients (47%) had a decrease in BMD, four patients (2%) had an increase in BMD, and six patients (32%) had no change. There was no correlation between metabolic markers and change in BMD. We suggest that ongoing management of patients who take imatinib should include monitoring of bone health on a long term basis.

Item Type: Paper
Uncontrolled Keywords: Absorptiometry, Photon Adult Aged Antineoplastic Agents/*adverse effects Benzamides/*adverse effects Biomarkers/metabolism Bone Density/*drug effects Bone Resorption/*chemically induced/diagnosis/metabolism Collagen Type I/metabolism Female Follow-Up Studies Gastrointestinal Stromal Tumors/*complications/drug therapy/mortality Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*complications/drug therapy/mortality Male Middle Aged Osteocalcin/metabolism Osteogenesis/*drug effects Peptides/metabolism Piperazines/*adverse effects Prognosis Prospective Studies Pyrimidines/*adverse effects Survival Rate Young Adult
Subjects: diseases & disorders > cancer > drugs and therapies
diseases & disorders > cancer > cancer types > gastrointestinal stromal tumors
diseases & disorders > cancer > cancer types > leukemia
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matt Covey
Date: July 2013
Date Deposited: 20 Oct 2016 15:54
Last Modified: 20 Oct 2016 15:54
Related URLs:
URI: http://repository.cshl.edu/id/eprint/33745

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving